Format

Send to

Choose Destination
See comment in PubMed Commons below
Jpn J Infect Dis. 2007 May;60(2-3):113-7.

Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan.

Author information

1
National Hospital Organization Nagoya Medical Center, Aichi 460-0001, Japan.

Abstract

Highly active antiretroviral therapy (HAART) can suppress human immunodeficiency virus type 1 (HIV-1) replication and plasma HIV-1 to below detectable levels. However, HAART becomes ineffective when drug-resistant viruses emerge during HAART. Monitoring drug-resistance mutations in viruses is necessary for selecting new drugs or therapies effective at inhibiting such HIV-1 variants. Most laboratories in Japan perform the tests using in-house protocols. However, the quality of these tests has never been assessed. Our study assessing the accuracy and reliability of HIV-1 genotypic drug-resistance testing in 15 laboratories in Japan revealed that the quality was very high (97.3% accurate). The errors, though rare, were caused by human errors, poor electropherograms, and the use of inadequate primers. Here, we propose troubleshooting procedures to improve testing accuracy and reliability in Japan.

PMID:
17515643
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for National Institute of Infectious Diseases
    Loading ...
    Support Center